Genmab A/ S stock (DK0010272202): earnings momentum and oncology pipeline keep investors watching

Genmab A/S remains in focus after recent quarterly results and ongoing progress in its oncology antibody portfolio. US-listed shares on Nasdaq give American investors direct exposure to the Danish biotech’s royalty streams and pipeline catalysts.

Genmab A/S has stayed on the radar of biotech-focused investors in recent weeks, as the Danish antibody specialist reported its latest quarterly results and highlighted continued growth in royalty revenue from key partnered cancer drugs as well as progress in its proprietary pipeline, according to a company earnings release published on 05/07/2026Genmab IR as of 05/07/2026. The stock is listed on Nasdaq under the ticker GMAB, offering US investors a way to participate in the company’s oncology-focused antibody platform and long-term collaboration agreements with large pharmaceutical groups.

As of: 19.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Genmab
• Sector/industry: Biotechnology / oncology therapeutics
• Headquarters/country: Copenhagen, Denmark
• Core markets: Cancer therapeutics in Europe, North America and other key pharma regions
• Key revenue drivers: Royalties and milestones from partnered antibody drugs plus sales of proprietary therapies
• Home exchange/listing venue: Nasdaq Copenhagen and Nasdaq (ADR GMAB)
• Trading currency: Danish krone in Copenhagen; US dollars on Nasdaq

Genmab A/S: core business model

Genmab A/S is a biotechnology company focused on the discovery and development of antibody-based therapies for cancer and other serious diseases. Its business model combines internal research capabilities with an extensive network of partnerships, allowing the company to develop antibodies using its proprietary technology platforms and then co-develop, license or out-license assets to larger pharmaceutical companies for later-stage development and commercializationGenmab website as of 05/2026. This structure reduces Genmab’s direct commercial infrastructure needs while providing access to global distribution channels for its products.

A central pillar of Genmab’s strategy is to build a diversified portfolio of antibody therapeutics that target different mechanisms in oncology. The company historically gained visibility through the anti-CD20 antibody ofatumumab, and its profile increased further with the success of the CD38-targeting antibody daratumumab, marketed by a larger partner. These collaborations usually involve upfront payments, development milestones, regulatory milestones and royalties on net sales, which can scale with the commercial performance of the partnered drugsGenmab investors as of 05/2026. As a result, Genmab’s revenue base contains a mix of relatively high-margin royalty streams and more volatile milestone income.

Beyond partnered projects, Genmab is increasingly pursuing its own proprietary medicines, sometimes co-commercialized with partners, to capture a larger share of the long-term value of its pipeline. This involves investments in clinical trials, regulatory submissions and, in some cases, building capabilities in medical affairs and select commercial functions, especially in hematology and oncology indications. The company emphasizes a data-driven, science-led approach, focusing on antibody engineering technologies such as bispecific antibodies and antibody-drug conjugates to address unmet medical needs in cancers like lymphoma, leukemia and solid tumors.

This hybrid model—combining royalty-generating partnerships with internally advanced assets—creates multiple income streams but also exposes Genmab to clinical, regulatory and commercial risks associated with the success of its own programs and those run by partners. For investors, this can translate into periods of strong revenue growth when successful drugs scale up, but also heightened share price volatility around clinical trial readouts, regulatory decisions and competitive developments in oncology.

Main revenue and product drivers for Genmab A/S

The most important revenue component for Genmab in recent years has been royalties from partnered antibody therapies, particularly in oncology. Daratumumab, a CD38-directed antibody indicated in multiple myeloma and other hematologic malignancies, has become a major contributor to Genmab’s royalty income through its partner’s global sales, according to the company’s annual report for 2024 published on 02/21/2025Genmab annual report as of 02/21/2025. As these therapies expand into additional treatment lines and new indications, Genmab’s royalty base can benefit, although it remains subject to competitive pressures and changes in treatment standards.

In its most recent quarterly earnings release for the period ending 03/31/2026, published on 05/07/2026, Genmab reported that total revenue for the quarter reached a level driven primarily by higher royalties from key partnered products and ongoing milestone recognition, while operating expenses reflected continued investment in research and development and commercialization supportGenmab Q1 2026 results as of 05/07/2026. The company reiterated its full-year 2026 financial guidance in the same release, framing the current year as a period of sustained investment in late-stage trials and potential label expansions.

Besides royalties, Genmab’s revenue structure includes milestone payments tied to specific development or regulatory events for partnered antibodies. These milestones are less predictable than ongoing royalties, as they depend on clinical and regulatory timelines, but they can lead to substantial one-time contributions when major milestones are achieved. Over a multi-year horizon, the combination of milestone receipts and growing royalties can provide a layered revenue profile, with some quarters showing stronger year-on-year comparisons than others based on the timing of events.

On the proprietary side, Genmab is working to advance several antibodies in hematologic cancers and solid tumors through Phase 2 and Phase 3 studies, often in combination with existing standard-of-care regimens. These pipeline candidates aim to leverage Genmab’s expertise in antibody design to improve efficacy or safety compared with established treatments, with some assets designed as bispecific antibodies that can engage multiple targets. Success in these programs could, over time, shift the revenue mix toward a higher proportion of direct product sales or profit-sharing arrangements, rather than predominantly third-party royalties.

For US investors specifically, Genmab’s listing on Nasdaq makes the stock accessible through standard brokerage accounts, and the company’s exposure to the US oncology market is significant because many of its key partnered products are approved or being evaluated by the US Food and Drug Administration. The US market remains one of the largest for cancer therapeutics; therefore, regulatory decisions, reimbursement dynamics and competitive developments in the United States can have a meaningful influence on Genmab’s long-term royalty and product sales potential. Monitoring FDA communications, major oncology conferences and clinical data updates is therefore central to assessing the company’s revenue trajectory.

Why Genmab A/S matters for US investors

Genmab A/S may appeal to US investors who are looking for exposure to innovative oncology therapies without focusing solely on early-stage, pre-revenue biotechnology names. The company’s royalty-generating collaborations provide a revenue base that is less binary than single-drug stories, while its proprietary pipeline offers potential upside from successful clinical development. Because the stock trades on Nasdaq under the ticker GMAB in US dollars, investors based in the United States can access it alongside other biotech and pharmaceutical holdings and compare it directly with sector peers.

From a strategic perspective, Genmab’s partnerships with large multinational pharmaceutical companies give it access to the commercialization infrastructure needed to launch cancer drugs in the United States, Europe and other major markets. This means that decisions by US payers, guidelines committees and oncologists can have a significant effect on the sales trajectories of the drugs that generate royalties for the company. Key data presentations at US-based oncology conferences such as ASCO or ASH often serve as catalysts for sentiment changes, as new trial results can either strengthen or challenge the outlook for specific therapies.

At the same time, US investors need to consider that Genmab reports financials in Danish kroner and is headquartered in Denmark, which introduces currency considerations and regulatory differences compared with purely domestic biotech firms. The company’s valuation and share price performance can also be influenced by European equity market sentiment, as Genmab shares trade on both Nasdaq Copenhagen and Nasdaq. Comparing reported figures using constant exchange rates, where provided, can help investors interpret growth trends more clearly across reporting periods, especially in an environment of fluctuating FX rates.

Conclusion

Genmab A/S occupies a distinctive position in the global oncology landscape, combining a portfolio of royalty-generating partnered therapies with an advancing pipeline of proprietary antibody candidates. Its recent quarterly report for the first quarter of 2026 underlined the importance of royalties from established cancer drugs, while also highlighting the company’s commitment to reinvesting in research and development to support future growth. For US investors, the Nasdaq listing and Genmab’s significant exposure to the American oncology market make the stock a relevant name in the biotech space, though it brings the typical risks of clinical development, regulatory outcomes and competitive pressure that characterize the sector. A balanced view therefore takes into account both the stability provided by current royalties and the uncertainty surrounding long-term pipeline success and market dynamics.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.